Consumer access to buprenorphine and methadone in certified community behavioral health centers: A secret shopper study.

[1]  B. Griffin,et al.  Buprenorphine prescriber monthly patient caseloads: An examination of 6-year trajectories. , 2021, Drug and alcohol dependence.

[2]  Lewis S. Nelson,et al.  Access to Medications for Opioid Use Disorder (MOUD) Among Residential Treatment Programs in the United States: A Pilot Secret Shopper Study , 2021 .

[3]  Michael Lawrence Barnett,et al.  Therapies Offered at Residential Addiction Treatment Programs in the United States. , 2020, JAMA.

[4]  Jonathan D. Brown,et al.  Implementation and Costs of the Certified Community Behavioral Health Clinic Demonstration , 2020 .

[5]  C. Brayne,et al.  Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16 , 2020, PloS one.

[6]  Michael Lawrence Barnett,et al.  Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality , 2019, Annals of Internal Medicine.

[7]  E. Stringfellow,et al.  The case for a medication first approach to the treatment of opioid use disorder , 2019, The American journal of drug and alcohol abuse.

[8]  N. Volkow,et al.  Management of opioid use disorder in the USA: present status and future directions , 2019, The Lancet.

[9]  G. Guy,et al.  County-Level Opioid Prescribing in the United States, 2015 and 2017 , 2019, JAMA internal medicine.

[10]  M. Olfson,et al.  Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities. , 2019, Health affairs.

[11]  E. Stringfellow,et al.  Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs. , 2019, Journal of substance abuse treatment.

[12]  Randall Young,et al.  Vital Signs: Changes in Opioid Prescribing in the United States, 2006–2015 , 2017, MMWR. Morbidity and mortality weekly report.

[13]  A. Huhn,et al.  Why aren't physicians prescribing more buprenorphine? , 2017, Journal of substance abuse treatment.

[14]  D. Bell,et al.  Chronic pain among patients with opioid use disorder: Results from electronic health records data. , 2017, Journal of substance abuse treatment.

[15]  Amy M. Cohn,et al.  Characteristics of U.S. Substance Abuse Treatment Facilities Offering HIV Services: Results From a National Survey. , 2016, Psychiatric services.

[16]  H. Knudsen,et al.  Adoption and Implementation of Medications in Addiction Treatment Programs , 2011, Journal of addiction medicine.

[17]  Lori J. Ducharme,et al.  The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. , 2007, Drug and alcohol dependence.

[18]  W. Kissin,et al.  Experiences of a National Sample of Qualified Addiction Specialists Who Have and Have Not Prescribed Buprenorphine for Opioid Dependence , 2006, Journal of addictive diseases.